PURE Bioscience to Present at LD MICRO Small & Micro Cap Stock Conference
SAN DIEGO, Calif. – April 21, 2008 – PURE Bioscience (NASDAQ: PURE),creators of patented silver dihydrogen citrate (SDC), the active ingredient in a revolutionary new hard surface disinfectant which kills Staph/MRSA as well as other human pathogens, today announced that Michael L. Krall, President and CEO of PURE Bioscience, will present at the inaugural LD MICRO Small & Micro Cap Stock Conference in Los Angeles, on Tuesday, April 29th, at 10:30 a.m. PST at The Omni Los Angeles at California Plaza. Krall will meet with institutional investors to discuss the Company’s growth and development.
LD MICRO publishes a by-invitation only newsletter focusing on discovering undervalued companies in the micro cap space overlooked by institutional investors. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select names throughout the year.
For more information on the 60 presenting companies or to register for the event, visit http://www.ldmicro.com or call 310-862-4512.
About PURE Bioscience
PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. PURE’s flagship technology, silver dihydrogen citrate (SDC), is an electrolytically generated source of stabilized ionic silver. A patented new molecular entity, SDC is distinguished from competitors because of its superior efficacy, reduced toxicity and the inability of bacteria to become resistant to it. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third-party products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products. PURE Bioscience, headquartered in
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.